[go: up one dir, main page]

AR126166A1 - Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos - Google Patents

Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos

Info

Publication number
AR126166A1
AR126166A1 ARP220101591A ARP220101591A AR126166A1 AR 126166 A1 AR126166 A1 AR 126166A1 AR P220101591 A ARP220101591 A AR P220101591A AR P220101591 A ARP220101591 A AR P220101591A AR 126166 A1 AR126166 A1 AR 126166A1
Authority
AR
Argentina
Prior art keywords
inhibitor
kras
combination
erk
pharmaceutically acceptable
Prior art date
Application number
ARP220101591A
Other languages
English (en)
Inventor
Bing Hou
Jian Wang
Bo Shan
Xingxing Wang
Yun Liu
Peng Chen
Hui Yuwen
Bin Jiang
Jay Mei
Original Assignee
Antengene Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Discovery Ltd filed Critical Antengene Discovery Ltd
Publication of AR126166A1 publication Critical patent/AR126166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente divulgación en general se refiere a la combinación de un inhibidor de ERK y un inhibidor de KRAS y usos de estos. Reivindicación 51: Una composición farmacéutica caracterizada porque comprende un inhibidor de KRAS o una sal farmacéuticamente aceptable de este, y un inhibidor de ERK o una sal farmacéuticamente aceptable de este.
ARP220101591A 2021-06-18 2022-06-16 Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos AR126166A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021100892 2021-06-18
CN2022095820 2022-05-28

Publications (1)

Publication Number Publication Date
AR126166A1 true AR126166A1 (es) 2023-09-27

Family

ID=84526853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101591A AR126166A1 (es) 2021-06-18 2022-06-16 Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos

Country Status (4)

Country Link
CN (1) CN117529321A (es)
AR (1) AR126166A1 (es)
TW (1) TW202317130A (es)
WO (1) WO2022262797A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081840A1 (en) 2021-11-05 2023-05-11 Frontier Medicines Corporation Kras g12c inhibitors
WO2023137223A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Pan-kras inhibitors and uses thereof
TW202508595A (zh) * 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI730012B (zh) * 2015-11-09 2021-06-11 瑞典商阿斯特捷利康公司 化學化合物
EP3269365A1 (en) * 2016-07-14 2018-01-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Kras inhibitor for use in treating cancer
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EA202091186A1 (ru) * 2017-11-15 2020-10-01 Мирати Терапьютикс, Инк. ИНГИБИТОРЫ KRas G12C
CN112830928A (zh) * 2019-11-22 2021-05-25 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
IL298670A (en) * 2020-06-04 2023-01-01 Antengene Discovery Ltd Inhibitors of kras g12c protein and uses thereof

Also Published As

Publication number Publication date
WO2022262797A1 (en) 2022-12-22
CN117529321A (zh) 2024-02-06
TW202317130A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
AR126166A1 (es) Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
CA3148745A1 (en) Kras g12d inhibitors
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2020013116A (es) Sales y cristales novedosos.
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
JOP20200336A1 (ar) طرق إعطاء مثبطات vmat2 معينة
UY26825A1 (es) Composción y actividad antiviral de derivados piperazina indoloxoacéticos sustituidos
PH12019550249A1 (en) Solid compositions for oral administration
CO2024006819A2 (es) Composiciones y tratamientos con nirogacestat
ES2183817T3 (es) Inibidores de proteasas de parasatiso metazoarios.
MX2025003008A (es) Regimen de dosificacion para el tratamiento de la pku con un inhibidor de la funcion de slc6a19 como piperidina
AR117600A1 (es) Formulaciones de un inhibidor de axl / mer
MXPA04001397A (es) Metodo y composiciones para el tratamiento y prevencion de dolor e inflamacion con un inhibidor selectivo de cicloxigenasa-2 y sulfato de condroitina.
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
MX2019003039A (es) Forma de dosificacion de alivio prolongado.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MY205335A (en) Compositions and methods for treating severe constipation
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
CL2022002317A1 (es) Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.

Legal Events

Date Code Title Description
FB Suspension of granting procedure